GeneDx CFO acquires 1,986 shares at $88.11

GeneDx Holdings Corp. chief financial officer Kevin Feeley acquired additional company stock in an insider transaction.

Rhea-AI Filing Summary

GeneDx Holdings Corp. chief financial officer Kevin Feeley acquired additional company stock in an insider transaction. On March 6, 2026, he obtained 1,986 shares of GeneDx Class A common stock directly from the company at $88.11 per share under a subscription agreement exempt under Rule 16b-3(d). After this award, his direct ownership increased to 20,660 shares of Class A common stock.

Insider Trade Summary

Grant/Award: 1,986 shares

Grant/Award 1 txn

Insider Feeley Kevin

Role CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	1,986	$88.11	$175K

Holdings After Transaction: Class A Common Stock — 20,660 shares (Direct)

Footnotes (1)

1. F1. Pursuant to a Subscription Agreement executed on March 6, 2026 between GeneDx Holdings Corp. (the "Issuer") and the reporting person, the reporting person acquired 1,986 shares of the Issuer's Class A common stock directly from the Issuer in an exempt transaction pursuant to Rule 16b-3(d) at a purchase price of $88.11 per share, the closing price of the Issuer's Class A common stock on March 6, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did GeneDx (WGS) report for CFO Kevin Feeley?

GeneDx reported that CFO Kevin Feeley acquired 1,986 shares of its Class A common stock. The shares were obtained directly from the company under a subscription agreement, recorded as an exempt insider transaction pursuant to Rule 16b-3(d).

At what price did the GeneDx (WGS) CFO acquire the new shares?

Kevin Feeley acquired the 1,986 GeneDx Class A shares at a purchase price of $88.11 per share. The price was set at the closing market price of GeneDx’s Class A common stock on March 6, 2026.

How many GeneDx (WGS) shares does CFO Kevin Feeley own after this transaction?

After the March 6, 2026 transaction, Kevin Feeley directly owns 20,660 shares of GeneDx Class A common stock. This figure reflects his holdings immediately following the 1,986-share acquisition from the company.

Was the GeneDx (WGS) CFO’s share acquisition an open-market purchase?

No, the acquisition was not an open-market purchase. Kevin Feeley received 1,986 Class A shares directly from GeneDx under a subscription agreement, in an exempt transaction pursuant to Rule 16b-3(d), rather than buying them on the open market.

What regulatory exemption applied to the GeneDx (WGS) CFO’s share acquisition?

The transaction was conducted as an exempt insider acquisition under Rule 16b-3(d). This rule allows certain transactions between an issuer and its officers or directors, like this subscription agreement, to avoid short-swing profit liability under U.S. securities laws.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/09/2026 - 07:56 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Feeley Kevin

(Last) (First) (Middle)

C/O GENEDX HOLDINGS CORP.

333 LUDLOW ST., NORTH TOWER, 6TH FLOOR

(Street)

STAMFORD CT 06902

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GeneDx Holdings Corp. [ WGS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock(1)	03/06/2026		A		1,986	A	$88.11	20,660	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Pursuant to a Subscription Agreement executed on March 6, 2026 between GeneDx Holdings Corp. (the "Issuer") and the reporting person, the reporting person acquired 1,986 shares of the Issuer's Class A common stock directly from the Issuer in an exempt transaction pursuant to Rule 16b-3(d) at a purchase price of $88.11 per share, the closing price of the Issuer's Class A common stock on March 6, 2026.

	/s/ Bridget Brown, Attorney-in-Fact	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.